ClinicalTrials.gg
RecruitingNCT04741711AMBUSHUpdated May 17, 2023

AMBulatory UltraSound for Heart Failure Management

An interventional study of An ultrasound (lung and inferior vena cava) will be performed and the heart failure treatments will be guided by the results of the lung ultrasound and the evaluation of the inferior vena cava. and Usual care without ultrasound guidance in Heart Failure, sponsored by Central Hospital, Nancy, France. Recruiting at 5 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-17.

Sponsored by Central Hospital, Nancy, France · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Heart Failure by Central Hospital, Nancy, France — 9 open to participants now, 10 under way, 1 of them phase 3. Heart Failure · Central Hospital, Nancy, France.

Planned enrollment
3rd of 13
182 · median 103
Started
2023
with 2 others
No phase
12 of 19
8 open now
Registered
11th of 19
by date

Among the 19 studies in Heart Failure by Central Hospital, Nancy, France, this one is the 3rd largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2023, is one of 12 with no phase, and was the 11th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

9 of the 19 studies in Heart Failure by Central Hospital, Nancy, France are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Heart Failure by Central Hospital, Nancy, France, or all of them as a file.
02

Study summary

AMBUSH study is a multicenter randomized, controlled, open-label clinical trial (PROBE (Prospective Randomized Open Blinded End-point) type).

The main objective of AMBUSH study is to assess the effect of therapeutic management guided by pulmonary ultrasound and the assessment of the inferior vena cava in patients with heart failure seen in an ambulatory (outpatient) setting on a mixed clinical-biological endpoint (including variations of natriuretic peptides - NtProBNP) at 30 days.

Read the detailed description

Secondary objectives are:

A. To assess the effect of therapeutic management guided by pulmonary ultrasound and inferior vena cava assessment on the risk of cardiovascular death and hospitalization for heart failure at 30 days.

B. Describe the proportion of ultrasound congestion (pulmonary and inferior vena cava data) in patients free from clinical congestion at baseline in the intervention group and in all patients at D30 visit.

C. Evaluate the association of ultrasound congestion (pulmonary and inferior vena cava assessment) with serum concentrations of natriuretic peptides at baseline and D30 visit.

D. Evaluate the association of variations in ultrasound congestion (pulmonary and evaluation of the inferior vena cava) and variations in natriuretic peptides between baseline and D30 visit.

E. Compare the proportion of ultrasound and clinical congestion in patients in the intervention group and in the control group at baseline and on D30 visit.

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 18 and over
  • Heart failure (regardless of )
  • Diagnosis of heart failure established more than 3 months ago
  • Absence of significant clinical signs of congestion on clinical examination (absence of crackles and lower limbs oedema greater than perimalleolar oedema)
  • Affiliation to social security
  • Receiving complete information about research organization and signed .

Exclusion criteria

Exclusion Criteria:

  • Natriuretic peptides result, carried out during the previous 30 days, available at the inclusion consultation
  • Pulmonary or pleural pathology preventing reliable acquisition of lung ultrasound images: severe emphysema, chronic pleurisy, pulmonary fibrosis.
  • Suspicion of cardiac amyloidosis or proven amyloidosis,
  • Patient with severe primary heart valve disease
  • Pregnant woman, parturient or nursing mother
  • Adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice)
  • Person deprived of liberty by a judicial or administrative decision,
  • Person subject to psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1 of the Public Health Code.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
182 participants (estimated)

Study arms

  • Experimental
    Interventional group

    The heart failure treatments will be guided by the results of the lung ultrasound and the evaluation of the inferior vena cava

    Procedure: An ultrasound (lung and inferior vena cava) will be performed and the heart failure treatments will be guided by the results of the lung ultrasound and the evaluation of the inferior vena cava.

  • Other
    Control group

    Usual care (i.e. without ultrasound guidance) will be provided.

    Procedure: Usual care without ultrasound guidance

Interventions

  • ProcedureAn ultrasound (lung and inferior vena cava) will be performed and the heart failure treatments will be guided by the results of the lung ultrasound and the evaluation of the inferior vena cava.

    An ultrasound (lung and inferior vena cava) will be performed and the heart failure treatments will be guided by the results of the lung ultrasound and the evaluation of the inferior vena cava. The choice of congestion treatment modalities to be implemented is left to the investigators' discretion, in accordance with European practice guidelines.

  • ProcedureUsual care without ultrasound guidance

    Usual care (i.e. without ultrasound guidance)

06

What researchers measure

Primary outcomes

  1. Death within 30 days (composite endpoint)

    The primary endpoint will rank patients from worst to most favourable outcome during the trial. It will be a hierarchical composite of events as described by Felker in 2010 (PMID 20841546).

    Time frame: Within 30 days

  2. Hospitalization for heart failure within 30 days (composite endpoint)

    The primary endpoint will rank patients from worst to most favourable outcome during the trial. It will be a hierarchical composite of events as described by Felker in 2010 (PMID 20841546).

    Time frame: Within 30 days

  3. Changes in N-terminal pro b-type natriuretic peptide (NtProBNP) between randomization and D30 (composite endpoint)

    The primary endpoint will rank patients from worst to most favourable outcome during the trial. It will be a hierarchical composite of events as described by Felker in 2010 (PMID 20841546).

    Time frame: Between randomization and Day 30

Secondary outcomes

  1. Cardiovascular death

    Within the combined outcome of CV death or hospitalization for heart failure. Outcomes will be adjudicated blinded from randomization arm

    Time frame: Within 30 days

  2. Ultrasound pulmonary congestion defined ≥3 B-lines on two intercostal spaces bilaterally (8-point method) and systemic congestion defined as an inferior vena cava diameter 21 mm or greater and/or a low variation during the respiratory cycle

    Time frame: At baseline in the intervention group and in all patients at Day 30 post inclusion

  3. Circulating levels of natriuretic peptides (NtProBNP)

    Time frame: At baseline and Day 30

  4. Changes in natriuretic peptides (NtProBNP)

    Time frame: Between baseline and Day 30.

  5. Ultrasound congestion defined as in B / and clinical congestion evaluated according to the EVEREST and ASCEND scores

    Time frame: At baseline in the intervention group and in all patients at the Day 30.

07

Study locations

1 of 5 sites recruiting
  • CHU de Besançon
    Besançon, 25030, France
    Not yet recruiting
    • Marie-France Seronde, MD · Contact
    • Marie-France Seronde, MD · Principal investigator
  • CH de Mulhouse
    Mulhouse, 68070, France
    Not yet recruiting
    • David Kenizou, MD · Contact
    • David Kenizou, MD · Principal investigator
  • CHRU de Reims
    Reims, 51092, France
    Not yet recruiting
    • Pierre Nazeyrolas, Md, PhD · Contact
    • Pierre Nazeyrolas, MD, PhD · Principal investigator
  • CHR de Metz
    Thionville, 57126, France
    Not yet recruiting
    • Noura Zannad, MD · Contact
    • Noura Zannad, MD · Principal investigator
  • CHRU de Nancy
    Vandoeuvre Les Nancy, 54500, France
    Recruiting
    • Nicolas GIRERD, MD, PhD · Contactn.girerd@chru-nancy.fr · +33 3 83 15 74 96
    • Nicolas GIRERD, MD, PhD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Jun 2026, 37 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 37 months is above that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2021
First posted
Feb 5, 2021
StartActual
May 15, 2023
Primary completionEst.
Jun 15, 2026
CompletionEst.
Jun 15, 2027
Last update
May 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04741711
Responsible party
Pr. Nicolas GIRERD (MD,PhD, Central Hospital, Nancy, France) — Principal investigator
First posted
Feb 5, 2021
Start date
May 15, 2023
Primary completion
Jun 15, 2026 (estimated)
Completion
Jun 15, 2027 (estimated)
Last update
May 17, 2023

Study contacts

Nicolas GIRERD, MD,PhD
Contact
n.girerd@chru-nancy.fr
+33 3 83 15 74 96 ext. +333

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion